Meag Munich Ergo, Kapitalanlagegesellschaft Mb H Incyte Corp Transaction History

Meag Munich Ergo, Kapitalanlagegesellschaft Mb H

$2.7 Billion
Q1 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 Apr 23, 2020	SELL	$63.18 - $85.97 $164,141 - $223,350	-2,598 Closed	0 $0
Q4 2019 Jan 17, 2020	SELL	$73.04 - $95.72 $692,857 - $907,999	-9,486 Reduced 78.5%	2,598 $229,000
Q3 2019 Oct 29, 2019	BUY	$72.82 - $86.52 $424,103 - $503,892	5,824 Added 93.04%	12,084 $876,000
Q1 2019 Apr 29, 2019	BUY	$63.56 - $88.17 $397,885 - $551,944	6,260 New	6,260 $536,000
Q1 2018 May 02, 2018	SELL	$83.06 - $100.98 $679,181 - $825,713	-8,177 Closed	0 $0

Q4 2017 Jan 26, 2018	BUY	$93.56 - $116.6 $765,040 - $953,438	8,177	8,177 $784,000

Others Institutions Holding INCY

# of Institutions

618

Shares Held

215M

Call Options Held

366K

Put Options Held

445K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $12.8B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Meag Munich Ergo, Kapitalanlagegesellschaft Mb H, based on Form 13F filings with the SEC.

News

Stay updated on Meag Munich Ergo, Kapitalanlagegesellschaft Mb H with notifications on news.

Account